Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084

For the first-line treatment of certain patients with metastatic non-small cell lung cancer

Abbott receives FDA approval for TriClip

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery

Max CMD Abhay Soi is new president of NATHEALTH

New leadership team announced at NATHEALTH Annual General Meeting 2024

Evonik unveils latest global trial results MetAMINO

Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine

Colgate Active Salt redefines oral hygiene with a new and improved formula

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia

Apotex to acquire Canadian Searchlight Pharma

Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals

Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours

Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus

Aurobindo Pharma commissions 4 plants in Andhra Pradesh including Pen-G and 6-APA facilities

These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.